HC Wainwright Has Positive Estimate for LYEL Q1 Earnings

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Lyell Immunopharma in a research note issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.17) per share for the quarter, up from their previous estimate of ($0.20). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma Price Performance

LYEL stock opened at $0.48 on Monday. Lyell Immunopharma has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The stock has a market capitalization of $142.80 million, a price-to-earnings ratio of -0.61 and a beta of -0.41. The business’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million for the quarter.

Insider Buying and Selling at Lyell Immunopharma

In other news, CEO Lynn Seely purchased 175,000 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were purchased at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 712,500 shares of the company’s stock, valued at $434,625. This trade represents a 32.56 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Charles W. Newton acquired 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the purchase, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 533,000 shares of company stock worth $313,550 over the last 90 days. Insiders own 25.10% of the company’s stock.

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of the stock. Centiva Capital LP purchased a new position in Lyell Immunopharma in the third quarter worth $31,000. Graham Capital Management L.P. bought a new position in Lyell Immunopharma in the 4th quarter worth about $33,000. RPO LLC bought a new position in Lyell Immunopharma in the 4th quarter worth about $42,000. Intech Investment Management LLC bought a new position in shares of Lyell Immunopharma during the 3rd quarter valued at about $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma during the 3rd quarter worth approximately $52,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.